Amylyx faces an uphill battle
Briefing documents show why the FDA should await more data on the ALS project, but will it bow to patient pressure?
Go or no go? Bristol’s Lag3 debut
March Pdufa dates are set for relatlimab as well as Akebia’s vadadustat, while Amylyx’s ALS drug heads for a panel.
Biotech investors pray for a takeover miracle
Three of the top five buyouts of 2021 happened in the final quarter, and with biotech stocks hurting many hope that the flurry will continue.
After a record year, where next for biopharma flotations?
2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.
Biogen leads the amyotrophic lateral sclerosis hopefuls
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
Amylyx changes its mind about an early filing
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.
